Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 26, 2020; 8(14): 3122-3129
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.3122
Published online Jul 26, 2020. doi: 10.12998/wjcc.v8.i14.3122
Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
Xing-Tong Wang, Wei Guo, Wei Han, Zhong-Hua Du, Xiu-Xiu Wang, Ou Bai, Department of Hematology, The First Hospital of Jilin University, Jilin Provincial Hematology Research Institute, National Key Discipline, Changchun 130021, Jilin Province, China
Mo Sun, Department of Pathology, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Bei-Bei Du, Department of Cardiology, The Third Hospital of Jilin University, Changchun, Jilin Province 130031, China
Author contributions: Wang XT, Guo W, and Bai O were the patient’s physicians; Sun M, Han W, and Du ZH performed the pathology diagnosis; Wang XX helped with the data acquisition; Wang XT, Du BB, and Bai O reviewed the literature and contributed to the manuscript drafting; Wang XT, Guo W, and Bai O were responsible for revising the manuscript for important intellectual content; All authors issued final approval for the version to be submitted.
Supported by a grant from the Department of Finance of Jilin Province , No. 2018SCZWSZX-031 .
Informed consent statement: Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ou Bai, MD, PhD, Chief Doctor, Professor, Deputy Director, Department of Hematology, The First Hospital of Jilin University, Jilin Provincial Hematology Research Institute, National key Discipline, No. 71, Xinmin Street, Changchun 130021, Jilin Province, China. baiou@jlu.edu.cn
Received: March 14, 2020
Peer-review started: March 14, 2020
First decision: April 22, 2020
Revised: April 26, 2020
Accepted: July 4, 2020
Article in press: July 4, 2020
Published online: July 26, 2020
Processing time: 132 Days and 9.4 Hours
Peer-review started: March 14, 2020
First decision: April 22, 2020
Revised: April 26, 2020
Accepted: July 4, 2020
Article in press: July 4, 2020
Published online: July 26, 2020
Processing time: 132 Days and 9.4 Hours
Core Tip
Core tip: Hepatosplenic T-cell lymphoma is a rare disease that progresses quickly and has a poor prognosis. Patients usually show short-term rapid disease progress with a traditional inductive regimen, leaving no opportunity for hematopoietic stem cell transplantation. We employed the histone deacetylase inhibitor chidamide combined with a dose-adjusted ifosfamide, carboplatin, etoposide regimen, and chidamide single-drug oral maintenance therapy for the management of this patient, which had a satisfactory outcome.